SEC Form 4
Sionna Therapeutics, Inc. (SION) insider trading
In the 12 months to Oct 26, 2026, 7 SION insiders reported open-market sales of $165.9M across 37 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $165.9M
- 37 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 28 of 37
- $112.6M of $165.9M sold (68%)
Who traded SION, and when
- Sale
- Sale, pre-arranged (10b5-1)
SION daily close from Oct 27, 2025 to Oct 26, 2026, between $3.60 and $51.04, last $3.69. 37 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Peter A. Thompson, Director: sold $55.7M across 10 filings, first filed Nov 26, 2025, last Jul 9, 2026. OrbiMed Capital GP VIII LLC, Director: sold $49.2M across 8 filings, first filed Nov 26, 2025, last Jul 9, 2026. Peter Kolchinsky, Director: sold $33.3M across 4 filings, first filed Oct 28, 2025, last Sep 21, 2026. Rajeev M. Shah, Director: sold $10.0M across 4 filings, first filed Oct 28, 2025, last Sep 21, 2026. James G. Coulter, 10% owner: sold $10.0M across 1 filing, first filed Jan 26, 2026, last Jan 26, 2026. ORBIMED ADVISORS LLC, Director: sold $6.5M across 7 filings, first filed Nov 26, 2025, last May 29, 2026. Jennifer Fitzpatrick, Chief Legal Officer: sold $1.2M across 3 filings, first filed Dec 9, 2025, last Jul 7, 2026.
Largest mark · tap a row for others
Peter A. Thompson · Director
Filing 1 of 2 within a week · $25,417,386 total
Sale $22,945,044
510,583 shares at $44.94 avg
Filed Apr 16, 2026 · traded Apr 14
Pre-arranged (10b5-1) · close on filing date $45.24
Peter A. Thompson · Director
Director
$55.7M soldOrbiMed Capital GP VIII LLC · Director
Director
$49.2M soldPeter Kolchinsky · Director
Director
$33.3M soldRajeev M. Shah · Director
Director
$10.0M soldJames G. Coulter · 10% owner
10% owner
$10.0M soldORBIMED ADVISORS LLC · Director
Director
$6.5M soldJennifer Fitzpatrick · Chief Legal Officer
Chief Legal Officer
$1.2M soldOpen-market trades
37 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Peter A. Thompson | Director | $55.7M | — | 10 | 100% of sales | |
| OrbiMed Capital GP VIII LLC | Director | $49.2M | — | 8 | 100% of sales | |
| Peter Kolchinsky | Director | $33.3M | — | 4 | — | |
| Rajeev M. Shah | Director | $10.0M | — | 4 | — | |
| James G. Coulter | 10% owner | $10.0M | — | 1 | — | |
| ORBIMED ADVISORS LLC | Director | $6.5M | — | 7 | 100% of sales | |
| Jennifer Fitzpatrick | Chief Legal Officer | $1.2M | — | 3 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Rajeev M. Shah Director | Sale | 33,800 | $7.46 | $252.1K | 3,448,812 | |
traded | Peter Kolchinsky Director | Sale | 3,415,011 | $6.32 | $21.6M | 3,482,612 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 85,918 | $44.86 | $3.9M | 2,469,959 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 85,918 | $44.86 | $3.9M | 2,469,959 | |
traded | Jennifer Fitzpatrick Chief Legal Officer | SalePre-arranged (10b5-1) | 10,250 | $43.60 | $446.9K | 0 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 115,844 | $45.50 | $5.3M | 2,555,877 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 115,844 | $45.50 | $5.3M | 2,555,877 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 101 | $44.49 | $4.5K | 2,671,721 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 101 | $44.49 | $4.5K | 2,671,721 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 48,546 | $44.61 | $2.2M | 2,916,228 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 244,406 | $45.82 | $11.2M | 2,671,822 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 292,952 | $45.62 | $13.4M | 2,671,822 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 52,397 | $44.68 | $2.3M | 2,967,722 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 2,948 | $44.52 | $131.2K | 2,964,774 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 55,345 | $44.67 | $2.5M | 2,964,774 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 47,814 | $44.51 | $2.1M | 3,482,888 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 462,769 | $44.98 | $20.8M | 3,020,119 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 510,583 | $44.94 | $22.9M | 3,020,119 | |
traded | Jennifer Fitzpatrick Chief Legal Officer | SalePre-arranged (10b5-1) | 10,250 | $33.86 | $347.0K | 0 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 30,953 | $44.58 | $1.4M | 3,530,702 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 30,953 | $44.58 | $1.4M | 3,530,702 | |
traded | James G. Coulter 10% owner | Sale | 250,000 | $40.00 | $10.0M | 6,494,962 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 33,356 | $44.55 | $1.5M | 3,561,655 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 33,356 | $44.55 | $1.5M | 3,561,655 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 1,875 | $44.49 | $83.4K | 3,595,011 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 1,775 | $44.50 | $79.0K | 3,595,011 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 100 | $44.49 | $4.4K | 3,595,886 | |
traded | Jennifer Fitzpatrick Chief Legal Officer | SalePre-arranged (10b5-1) | 10,250 | $40.52 | $415.3K | 0 | |
traded | Peter A. Thompson Director | SalePre-arranged (10b5-1) | 108,073 | $44.55 | $4.8M | 3,596,886 | |
traded | OrbiMed Capital GP VIII LLC Director | SalePre-arranged (10b5-1) | 94,583 | $44.54 | $4.2M | 3,610,376 | |
traded | ORBIMED ADVISORS LLC Director | SalePre-arranged (10b5-1) | 13,490 | $44.59 | $601.5K | 3,596,886 | |
traded | Rajeev M. Shah Director | Sale | 19,000 | $39.60 | $752.3K | 159,033 | |
traded | Peter Kolchinsky Director | Sale | 11,316 | $39.62 | $448.4K | 650,307 | |
traded | Rajeev M. Shah Director | Sale | 114,017 | $40.37 | $4.6M | 168,202 | |
traded | Peter Kolchinsky Director | Sale | 22,334 | $40.16 | $896.8K | 6,899,079 | |
traded | Peter Kolchinsky Director | Sale | 262,045 | $39.52 | $10.4M | 2,240,708 | |
traded | Rajeev M. Shah Director | Sale | 111,565 | $39.50 | $4.4M | 6,905,625 |
GET /stocks/filings/vX/form-4?tickers=SION&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SION"
],
"issuer_cik": "0002036042",
"owner_cik": "0001619841",
"accession_number": "0001231919-26-001201",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-17",
"issuer_name": "Sionna Therapeutics, Inc.",
"issuer_trading_symbol": "SION",
"owner_name": "Shah Rajeev M.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 33800,
"transaction_price_per_share": 7.46,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3448812,
"transaction_value": 252148,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
},
{
"id": "F1",
"description": "RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
},
{
"id": "F2",
"description": "Held directly by the Fund."
}
],
"remarks": "Dr. Joshua Resnick, a Partner of the Adviser, serves on the Issuer's board of directors."
},
{
"tickers": [
"SION"
],
"issuer_cik": "0002036042",
"owner_cik": "0001315082",
"accession_number": "0001231919-26-001201",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-17",
"issuer_name": "Sionna Therapeutics, Inc.",
"issuer_trading_symbol": "SION",
"owner_name": "RA Capital Healthcare Fund LP",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 3415011,
"transaction_price_per_share": 6.32,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3482612,
"transaction_value": 21582869.52,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F1",
"description": "RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
},
{
"id": "F2",
"description": "Held directly by the Fund."
}
],
"remarks": "Dr. Joshua Resnick, a Partner of the Adviser, serves on the Issuer's board of directors."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 11 records
- Option exercises3 records
- Grants and awards8 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Sionna Therapeutics, Inc.'s CEO sold stock?
No. Michael Cloonan (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is SION’s insider data?
These are SION Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SION insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SION every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.